[go: up one dir, main page]

MX2007007277A - Metodos para tratar trastornos autoinmunes. - Google Patents

Metodos para tratar trastornos autoinmunes.

Info

Publication number
MX2007007277A
MX2007007277A MX2007007277A MX2007007277A MX2007007277A MX 2007007277 A MX2007007277 A MX 2007007277A MX 2007007277 A MX2007007277 A MX 2007007277A MX 2007007277 A MX2007007277 A MX 2007007277A MX 2007007277 A MX2007007277 A MX 2007007277A
Authority
MX
Mexico
Prior art keywords
methods
autoimmune disorders
treating autoimmune
treating
autoimmune disorder
Prior art date
Application number
MX2007007277A
Other languages
English (en)
Inventor
Nico Ghilardi
Frederic Desauvage
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2007007277A publication Critical patent/MX2007007277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invencion se refiere a metodos para tratar trastornos autoinmunes. En una modalidad, la invencion se dirige a un metodo para tratar un trastorno autoinmune que comprende administrar un agonista de TCCR. En una modalidad, el trastorno autoinmune es por lo menos parcialmente mediado por una respuesta de Th1. En una modalidad, el trastorno autoinmune es al menos parcialmente mediado por la proliferacion de CD8+celulas T.
MX2007007277A 2004-12-16 2005-12-16 Metodos para tratar trastornos autoinmunes. MX2007007277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63684604P 2004-12-16 2004-12-16
US74836705P 2005-12-06 2005-12-06
PCT/US2005/045603 WO2006066088A2 (en) 2004-12-16 2005-12-16 Methods for treating autoimmune disorders

Publications (1)

Publication Number Publication Date
MX2007007277A true MX2007007277A (es) 2008-01-28

Family

ID=36588594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007277A MX2007007277A (es) 2004-12-16 2005-12-16 Metodos para tratar trastornos autoinmunes.

Country Status (11)

Country Link
US (2) US20060177436A1 (es)
EP (1) EP1828250A2 (es)
JP (1) JP2008524242A (es)
KR (1) KR20070095949A (es)
AU (1) AU2005316405A1 (es)
BR (1) BRPI0517202A (es)
CA (1) CA2591587A1 (es)
IL (1) IL183985A0 (es)
MX (1) MX2007007277A (es)
RU (1) RU2007126985A (es)
WO (1) WO2006066088A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1095001A (en) * 1999-10-20 2001-04-30 Genentech Inc. Type i cytokine receptor tccr
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2657763C (en) 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
EA024654B1 (ru) * 2008-04-29 2016-10-31 Эмджен Рисерч (Мьюник) Гмбх Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010118243A2 (en) * 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
HRP20180959T1 (hr) 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
KR101351121B1 (ko) * 2011-02-18 2014-01-14 가톨릭대학교 산학협력단 Ｉｌ－２７을 유효성분으로 포함하는 면역거부질환의 예방 또는 치료용 조성물
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN105307725B (zh) 2013-04-11 2020-06-16 布里格姆及妇女医院股份有限公司 治疗自身免疫疾病的方法和组合物
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物
IL314925A (en) 2015-08-18 2024-10-01 Regeneron Pharma Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
EP3917618A1 (en) 2019-01-31 2021-12-08 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
EP3959240A1 (en) 2019-04-24 2022-03-02 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7382625B2 (ja) * 2019-08-29 2023-11-17 国立大学法人 鹿児島大学 掻痒治療剤
AU2021339381A1 (en) * 2020-08-05 2023-03-23 Synthekine, Inc. Compositions and methods related to receptor pairings
KR20250127176A (ko) * 2020-08-05 2025-08-26 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
WO2022031871A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Compositions and methods related to il27 receptor binding
US20250295719A1 (en) * 2022-05-31 2025-09-25 The Research Institute At Nationwide Children's Hospital Il-27 expressing oncolytic viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0672142B1 (en) * 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU2937597A (en) * 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
AU1095001A (en) * 1999-10-20 2001-04-30 Genentech Inc. Type i cytokine receptor tccr
EP1505148B1 (en) * 2002-04-26 2009-04-15 Chugai Seiyaku Kabushiki Kaisha Methods of screening for agonistic antibodies
DE60336930D1 (de) * 2002-12-31 2011-06-09 Schering Corp IL-27 et IL-2 pour le traitement du cancer
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response

Also Published As

Publication number Publication date
WO2006066088A2 (en) 2006-06-22
US20090280082A1 (en) 2009-11-12
US20060177436A1 (en) 2006-08-10
CA2591587A1 (en) 2006-06-22
AU2005316405A1 (en) 2006-06-22
EP1828250A2 (en) 2007-09-05
BRPI0517202A (pt) 2008-09-30
JP2008524242A (ja) 2008-07-10
IL183985A0 (en) 2008-12-29
WO2006066088A3 (en) 2007-02-22
RU2007126985A (ru) 2009-01-27
KR20070095949A (ko) 2007-10-01

Similar Documents

Publication Publication Date Title
MX2007007277A (es) Metodos para tratar trastornos autoinmunes.
NL301145I1 (es)
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
MX2020003223A (es) Tratamiento de enfermedades con ésteres de agonistas de rxr selectivos.
EP3358529A3 (en) Lightfield rendering based on depths from physically-based volume rendering
UA103634C2 (en) Azaindazole compounds as ccr1 receptor antagonists
GB0805703D0 (en) Apparatus, systems and methods for targeted content delivery
MX2008013135A (es) Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras condiciones caracterizadas por la masa osea baja, y combinacion de terapia que se relaciona con los mismos.
MXPA05013773A (es) Metodo para elaborar carboxialquilcelulosa.
WO2009126643A3 (en) Method and apparatus for delivering and caching multiple pieces of content
TW200942671A (en) Illuminated tiling system
EP1953726A3 (en) Traffic information distribution method, traffic information distribution apparatus and in-vehicle terminal
MX2010000481A (es) Sistemas y metodos para integrar sistemas de software educativo.
MX2009006794A (es) Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.
MX2010009872A (es) Procesamiento de video.
TW200519067A (en) Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality
NZ577392A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
MX2009013982A (es) Composiciones que comprenden inhibidores de triptofano hidroxilasa.
ZA202206807B (en) Genotype stratification in diabetes treatment and prevention
TW200531679A (en) Methods of modulating cytokine activity; related reagents
TW200621244A (en) Modulators of muscarinic receptors
WO2012033901A3 (en) Somatostatin receptor-based cancer therapy
EP1799106A4 (en) METHOD AND APPARATUS FOR INDICATING THE LEVEL OF VIGILANCE OF A SUBJECT
IL182962A0 (en) A method for generating a composite image
MX2007006382A (es) Moduladores de receptores muscarinicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal